Investigating fibrosis and inflammation in an ex vivo NASH murine model
- 1 February 2020
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 318 (2) , G336-G351
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, characterized by excess fat accumulation (steatosis). Nonalcoholic steatohepatitis (NASH) develops in 15-20% of NAFLD patients, and frequently progresses to liver fibrosis and cirrhosis. We aimed to develop an ex vivo model of inflammation and fibrosis in steatotic murine precision-cut liver slices (PCLS). NASH was induced in C57Bl/6 mice using amylin and choline-deficient L-amino acid-defined (CDAA) diet. PCLS were prepared from steatohepatitic (sPCLS) and control (cPCLS) livers and cultured for 48h with LPS, TGFβ1 or elafibranor. Additionally, C57Bl/6 mice were placed on CDAA diet for 12 weeks, to receive elafibranor or vehicle from week 7-12. Effects were assessed by transcriptome analysis and pro-collagen Iα1 protein production. The diets induced features of human NASH. Upon culture, all PCLS showed an increased gene expression of fibrosis and inflammation related markers, but decreased lipid metabolism markers. LPS and TGFβ1 affected sPCLS more pronouncedly than cPCLS. TGFβ1 increased pro-collagen Iα1 solely in cPCLS. Elafibranor ameliorated fibrosis and inflammation in vivo, but not ex vivo, where it only increased the expression of genes modulated by PPARα. sPCLS culture induced inflammation, fibrosis and lipid metabolism related transcripts, explained by spontaneous activation. sPCLS remained responsive to pro-inflammatory and profibrotic stimuli on gene expression. We consider that PCLS represent a useful tool to reproducibly study NASH progression. sPCLS can be used to evaluate potential treatments for NASH, as demonstrated in our elafibranor study, and serves as a model to bridge results from rodent studies to the human system.Keywords
Funding Information
- ZonMw (114025003)
- EU Horizon 2020 (634413, 777377)
- German Research Foundation (DFG CRC 1066/B3, DFG CRC 1292/08)
This publication has 69 references indexed in Scilit:
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s GuideNutrients, 2017
- Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advancesThe Journal of Pathology, 2016
- Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acidJournal of Hepatology, 2016
- Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLDSaudi Journal of Gastroenterology, 2012
- Differential expression of lumican and fatty acid binding protein-1: New insights into the histologic spectrum of nonalcoholic fatty liver disease #Hepatology, 2009
- Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non‐alcoholic steatohepatitisLiver International, 2008
- Phosphatidylcholine Homeostasis and Liver FailureJournal of Biological Chemistry, 2005
- A Choline-deficient Diet in Mice Inhibits neither the CDP-choline Pathway for Phosphatidylcholine Synthesis in Hepatocytes nor Apolipoprotein B SecretionJournal of Biological Chemistry, 2004
- Dietary choline restriction causes complex I dysfunction and increased H2O2 generation in liver mitochondriaCarcinogenesis, 2000